ICCC vs PETZ vs ELAN vs IDXX

For growth investors, TDH Holdings, Inc.

(PETZ) is the stronger pick with 122. 0% revenue growth year-over-year, versus 6. 2% for Elanco Animal Health Incorporated (ELAN). TDH Holdings, Inc. (PETZ) offers the better valuation at 5. 6x trailing P/E, making it the more compelling value choice. Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TDH Holdings, Inc.

(PETZ) is the cheapest at 5. 6x versus IDEXX Laboratories, Inc. at 42. 8x. On forward P/E, Elanco Animal Health Incorporated is actually cheaper at 22. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +6. 6%, compared to -97. 7% for TDH Holdings, Inc. (PETZ). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus PETZ's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TDH Holdings, Inc.

(PETZ) is the lower-risk stock at 0. 29β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 401% more volatile than PETZ relative to the S&P 500. On balance sheet safety, TDH Holdings, Inc. (PETZ) carries a lower debt/equity ratio of 13% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TDH Holdings, Inc.

(PETZ) is pulling ahead at 122. 0% versus 6. 2% for Elanco Animal Health Incorporated (ELAN). On earnings-per-share growth, the picture is similar: ImmuCell Corporation grew EPS 65. 3% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, ICCC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TDH Holdings, Inc.

(PETZ) is the more profitable company, earning 143. 8% net margin versus -8. 1% for ImmuCell Corporation — meaning it keeps 143. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -146. 3% for PETZ. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Elanco Animal Health Incorporated (ELAN) trades at 22.

4x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 15. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 33. 5% to $747. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ImmuCell Corporation (ICCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

38)). Both have compounded well over 10 years (ICCC: +16. 2%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ICCC (Healthcare) and PETZ (Consumer Defensive) and ELAN (Healthcare) and IDXX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICCC is a small-cap high-growth stock; PETZ is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock; IDXX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.